Monrad Joshua T, Sandbrink Jonas B, Cherian Neil G
Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Department of Health Policy, London School of Economics, London, UK.
NPJ Vaccines. 2021 Feb 11;6(1):26. doi: 10.1038/s41541-021-00290-y.
The ongoing COVID-19 pandemic has demonstrated the importance of rapid and versatile development of emergency medical countermeasures such as vaccines. We discuss the role of platform vaccines and prototype pathogen research in modern vaccine development, and outline how previous pathogen-specific funding approaches can be improved to adequately promote vaccine R&D for emerging pandemics. We present a more comprehensive approach to financing vaccine R&D, which maximises biomedical pandemic preparedness by promoting flexible vaccine platforms and translatable research into prototype pathogens. As the numerous platform-based SARS-CoV-2 vaccines show, funders can accelerate pandemic vaccine development by proactively investing in versatile platform technologies. For certain emerging infectious diseases, where vaccine research can translate to other related pathogens with pandemic potential, investment decisions should reflect the full social value of increasing overall preparedness, rather than just the value of bringing a vaccine to market for individual pathogens.
持续的新冠疫情已彰显了快速且灵活地开发如疫苗等紧急医疗应对措施的重要性。我们探讨了平台疫苗和原型病原体研究在现代疫苗开发中的作用,并概述了如何改进以往针对特定病原体的资助方式,以充分推动针对新发大流行疾病的疫苗研发。我们提出了一种更全面的疫苗研发融资方法,通过推广灵活的疫苗平台以及将研究转化为原型病原体来最大限度地提高生物医学大流行防范能力。正如众多基于平台的新冠病毒疫苗所显示的那样,资助者可以通过积极投资通用平台技术来加速大流行疫苗的开发。对于某些新兴传染病,其疫苗研究可转化应用于其他具有大流行潜力的相关病原体,投资决策应反映出提高整体防范能力的全部社会价值,而不仅仅是为个别病原体推出疫苗的价值。